[Heparin-induced thrombocytopenia].
Koide
M
M
Department of Internal Medicine, Hyogo Prefectural Awaji Hospital.
Matsuo
T
T
D000925:Anticoagulants / Q000009:adverse effects*; D000991:Antithrombins / Q000627:therapeutic use; D001120:Arginine / Q000031:analogs & derivatives; D001241:Aspirin / Q000627:therapeutic use; D003937:Diagnosis, Differential; D005343:Fibrinolytic Agents / Q000009:adverse effects*; D006493:Heparin / Q000009:adverse effects* / Q000276:immunology; D006801:Humans; D010875:Pipecolic Acids / Q000627:therapeutic use; D015539:Platelet Activation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D013449:Sulfonamides; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy; D013927:Thrombosis / Q000188:drug therapy / Q000209:etiology
D000925:Anticoagulants; D000991:Antithrombins; D005343:Fibrinolytic Agents; D010875:Pipecolic Acids; D010975:Platelet Aggregation Inhibitors; D013449:Sulfonamides; D006493:Heparin; D001120:Arginine; C031942:argatroban; D001241:Aspirin